
## Satoshi Ishii

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3055068/publications.pdf Version: 2024-02-01



SATOCUI ICUII

#	Article	IF	CITATIONS
1	Role of cytosolic phospholipase A2 in allergic response and parturition. Nature, 1997, 390, 618-622.	27.8	691
2	Acute lung injury by sepsis and acid aspiration: a key role for cytosolic phospholipase A2. Nature Immunology, 2000, 1, 42-46.	14.5	294
3	Identification of T Cell Death-associated Gene 8 (TDAG8) as a Novel Acid Sensing G-protein-coupled Receptor. Journal of Biological Chemistry, 2005, 280, 9083-9087.	3.4	166
4	Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype. American Journal of Human Genetics, 2002, 70, 994-1002.	6.2	146
5	Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochemical Journal, 2007, 406, 285-295.	3.7	129
6	Platelet-activating factor receptor. Prostaglandins and Other Lipid Mediators, 2002, 68-69, 599-609.	1.9	120
7	Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins and Other Lipid Mediators, 2009, 89, 57-65.	1.9	67
8	Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 250-257.	3.8	66
9	Interaction between neurone and microglia mediated by platelet-activating factor. Genes To Cells, 2000, 5, 397-406.	1.2	62
10	Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genetics in Medicine, 2019, 21, 44-52.	2.4	61
11	Airway Responsiveness in Transgenic Mice Overexpressing Platelet-activating Factor Receptor. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1621-1627.	5.6	56
12	Pharmacological chaperone therapy for Fabry disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2012, 88, 18-30.	3.8	52
13	Platelet-Activating Factor Receptor Develops Airway Hyperresponsiveness Independently of Airway Inflammation in a Murine Asthma Model. Journal of Immunology, 2004, 172, 7095-7102.	0.8	48
14	A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochemical Journal, 2013, 456, 373-383.	3.7	47
15	Platelet-activating factor receptor is not required for long-term potentiation in the hippocampal CA1 region. European Journal of Neuroscience, 1999, 11, 1313-1316.	2.6	37
16	Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 723-731.	2.5	37
17	Screening of Male Dialysis Patients for Fabry Disease by Plasma Globotriaosylsphingosine. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 629-636.	4.5	31
18	Reduced pain behaviors and extracellular signalâ€related protein kinase activation in primary sensory neurons by peripheral tissue injury in mice lacking plateletâ€activating factor receptor. Journal of Neurochemistry, 2007, 102, 1658-1668.	3.9	29

**SATOSHI ІSHII** 

#	Article	IF	CITATIONS
19	Accelerated proliferation of epidermal keratinocytes by the transgenic expression of the platelet-activating factor receptor. Archives of Dermatological Research, 1999, 291, 614-621.	1.9	26
20	Increased globotriaosylceramide levels in a transgenic mouse expressing human Â1,4-galactosyltransferase and a mouse model for treating Fabry disease. Journal of Biochemistry, 2011, 149, 161-170.	1.7	14
21	Medullary thick ascending limb impairment in the <i> Gla <sup>tm</sup> Tg(CAGâ€A4GALT </i> ) Fabry model mice. FASEB Journal, 2018, 32, 4544-4559.	0.5	14
22	The atypical Nâ€glycosylation motif, Asnâ€Cysâ€Cys, in human GPR109A is required for normal cell surface expression and intracellular signaling. FASEB Journal, 2015, 29, 2412-2422.	0.5	13
23	Histidine-Tagged Shiga Toxin B Subunit Binding Assay: Simple and Specific Determination of Gb3 Content in Mammalian Cells. Chemical and Pharmaceutical Bulletin, 2006, 54, 522-527.	1.3	6
24	Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease. Journal of Biological Chemistry, 2020, 295, 5577-5587.	3.4	6